​

Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

ForecastRevenueOwnershipFinancialsChartTranscripts
Acumen Pharmaceuticals by TradingView

Previous Close

$2.20

52W Range

$0.85 - $3.36

50D Avg

$1.63

200D Avg

$1.35

Market Cap

$138.71M

Avg Vol (3M)

$336.31K

Beta

0.20

Div Yield

-

ABOS Company Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

61

IPO Date

Jul 01, 2021

Website

ABOS Performance

ABOS Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-114.02M$-61.14M$-45.24M
Net Income$-102.33M$-52.37M$-40.48M
EBITDA$-114.02M$-51.61M$-42.69M
Basic EPS$-1.71$-1.08$-1.00
Diluted EPS$-1.71$-1.08$-1.00

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Aug 12, 25 | 12:00 AM
Q1 25May 13, 25 | 8:00 AM
Q4 24Mar 27, 25 | 8:00 AM

Peer Comparison

TickerCompany
IRDOpus Genetics, Inc.
MOLNMolecular Partners AG
CCCCC4 Therapeutics, Inc.
SPROSpero Therapeutics, Inc.
TVGNTevogen Bio Holdings Inc.
AGENAgenus Inc.
INOInovio Pharmaceuticals, Inc.
TILInstil Bio, Inc.
PEPGPepGen Inc.